drugset
drugset / Trial / NCT07250048

A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood

NCT07250048 ↗

Phase 1 Terminated 40 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Single-rising dose (SRD) part: The main objectives of the SRD part of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 3009947 in healthy participants following oral administration of single rising doses. Bioavailability (BA) part: The main objective of the BA part is to investigate the relative bioavailability of two different BI 3009947 formulations (Formulation A and B) and to assess the influence of food on the relative bioavailability of Formulation A or B.

Timeline

Start
2025-11-21
Primary completion
2026-03-02
Completion
2026-03-02

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3009947 Unknown — Oral

Indications

No indication recorded.